Publicaciones en colaboración con investigadores/as de Hospital Virgen del Camino (32)

2023

  1. Transmitted drug resistance to antiretroviral drugs in Spain during the period 2019–2021

    Journal of Medical Virology, Vol. 95, Núm. 12

  2. Venous thromboembolism characteristics, treatment and outcomes in young adults: findings from the Registro Informatizado de Enfermedad TromboEmbólica registry

    Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 10, pp. 2811-2823

2022

  1. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

    Blood cancer journal, Vol. 12, Núm. 4, pp. 68

  2. CM-352 Efficacy in a Mouse Model of Anticoagulant-Associated Intracranial Hemorrhage

    Thrombosis and Haemostasis, Vol. 122, Núm. 8, pp. 1314-1325

  3. Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study

    European Journal of Cancer, Vol. 174, pp. 243-250

2021

  1. A dna methylation-based gene signature can predict triple-negative breast cancer diagnosis

    Biomedicines, Vol. 9, Núm. 10

  2. Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies

    Blood Cancer Journal, Vol. 11, Núm. 12

  3. Inside the Thrombus: Association of Hemostatic Parameters With Outcomes in Large Vessel Stroke Patients

    Frontiers in Neurology, Vol. 12

  4. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

    Blood Cancer Journal, Vol. 11, Núm. 5

  5. Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 6, pp. 413-420

  6. Understanding the molecular mechanism of mir-877-3p could provide potential biomarkers and therapeutic targets in squamous cell carcinoma of the cervix

    Cancers, Vol. 13, Núm. 7

2020

  1. A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia

    Blood Cancer Journal, Vol. 10, Núm. 1

  2. Absence of nuclear p16 is a diagnostic and independent prognostic biomarker in squamous cell carcinoma of the cervix

    International Journal of Molecular Sciences, Vol. 21, Núm. 6

  3. Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma

    Leukemia, Vol. 34, Núm. 11, pp. 3007-3018

  4. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination

    Leukemia, Vol. 34, Núm. 2, pp. 589-603

2019

  1. Analysis of monocitary subpopulations in relation to cardiovascular risk factors

    Clinica e Investigacion en Arteriosclerosis, Vol. 31, Núm. 4, pp. 152-159

  2. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

    Blood, Vol. 134, Núm. 16, pp. 1337-1345

2018

  1. Effective cancer immunotherapy in mice by polyIC-imiquimod complexes and engineered magnetic nanoparticles

    Biomaterials, Vol. 170, pp. 95-115

2017

  1. CDH22 hypermethylation is an independent prognostic biomarker in breast cancer

    Clinical Epigenetics, Vol. 9, Núm. 1

  2. CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer

    Oncotarget, Vol. 8, Núm. 9, pp. 15789-15801